Research indicates that trauma among patients on anti-factor Xa drugs can produce life-threatening major bleeding in the absence of a reversal agent. Andexanet alfa is a specific reversal agent that acts as a factor Xa decoy to bind molecules that target factor Xa, thus reversing their activity. For a substudy of the ANNEXA-4 trial, patients aged approximately 81, among whom 47% were men and about 87% were taking apixaban or rivaroxaban to prevent blood clots that could lead to strokes due to atrial fibrillation, received an andexanet alfa infusion upon experiencing an adjudicated traumatic intracranial hemorrhage. Among them, 83.9% achieved excellent or good hemostasis within 12 hours of andexanet alfa delivery, with an excellent outcome defined as a 0% to 20% increase from baseline in volume or thickness of the hemorrhage and a good result as a 20% to 35% increase from baseline of the hemorrhage. The 30-day mortality rate among participants was 10.1%. Andexanet alft treatment reduced anti-factor Xa activity by 94.3% in patients on apixaban and by 91.8% in those on rivaroxaban.
×
Advertisement
Meeting Coverage
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.
- CROI 2020Every year, CROI hosts some of the world's leading experts in HIV research, who come to present exciting new data and drive forward the field of HIV/AIDS research. This year, due to COVID-19, CROI held their meeting virtually.